board of directors

Richard Ferrari

Co-founder of De Novo Ventures, one of the premier firms dedicated to medical devices and biotechnology with $650 million under management.  Mr. Ferrari has raised over a billion dollars for companies he has directly influenced and participated in approximately $1.5 billion in acquisition events.  Additionally, he has been a successful CEO of two publicly traded medical technology companies including Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters which was eventually acquired for $125 million by Boston Scientific, and CardioThoracic Systems (CTS), the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, which was acquired by Guidant for $350 million.  

Mr. Ferrari is the recipient of the Mallinckrodt Award for Excellence in Medicine and has been a finalist for the Entrepreneur of the Year Award.  He holds a BS degree from Ashland University and an MBA from the University of South Florida.

Robert V. House

Dr. House is an independent consultant and was previously Senior Vice President, Government Contracts of Ology Bioservices, with over 20 years' experience leading the contract management and oversight process of major US Government contracts with various agencies including the DoD, NIH, HHS, and other federal entities.   He is also a director of Arrevus, Inc.  He has more than 76 peer reviewed publications, plus numerous review articles, book chapters, and books.  In addition, he is an adjunct professor at George Mason University.

Dr. House is a graduate of the University of North Carolina at Chapel Hill, where he received his BA (Zoology) , his MS in Public Health, and his PhD (Medical Parasitology). He will play a major role in our non-dilutive financing initiative. 

Suha Jhaveri

Chief Commercial Officer and Head of Business Development for Leyden Labs. Previously Vice President, Market Development for VIR Biotechnology in San Francisco and before that, she was Global Commercial Leader, New Product Planning for Ultragenyx Pharmaceuticals.  Earlier positions include Chief Operating Officer for OBMedical Company and several management positions with Genentech, Chiron Corporation/Novartis, and other life science therapeutic and medical device companies. Early in her career, she was a consultant with Boston Consulting Group.

Ms. Jhaveri received an MBA from Harvard University, a masters in economic development from the University of Sussex, and a BA with honors from Stanford.

Stephanie Warrington

Chief Commercial Officer for Aurita, a 3D Bioscience company designed to bridge the gap between research and clinical settings. Ms. Warrington has over 25 years of experience as a healthcare and medical device consultant. Previously, she was a co-Founder, Director, and President of TrueMotion Spine (a seed-stage medical device company), President of Synogen, Inc. (a private equity venture fund), and Co-founder and VP of Corporate Development for Xhale, Inc., a medical device company recently acquired by Philips Healthcare. She has also participated as a key management team member in the launch and growth of several high-tech start-up companies and served as Chairman for Bioflorida, the premier organization for Florida's life sciences industry. 

Ms. Warrington obtained her BS in Business Administration, MBA. and MHA all from the University of Florida.